Cohort 6 ended. A terminal patient with STS is showing a reduction in tumour volume. This is a patient who has tried all standard dosing regimes of chemo and radiotherapy, and selflessly volunteered for a trial knowing its sole purpose was to see if the platform was safe for the benefit of others in years to come- it being something that would extend their life wasnt even considered a viable outcome.
Cohort 7 will be final cohort, amazingly they’ve been unable to find a max tolerable dose, so will be using a biological effective dose instead - this is unheard of with chemotherapy and shows how safe the platform is. A “paradigm shift” in the way cancer will be treated is the words of the CEO.
Even better is that phase 2 is being fast tracked to next year in the US and phase 1b is instead replaced with a short trial to decide if two weeks or three weeks dosing is better.
Best news however is that funding for phase 2 will come from either licensing and/or partnerships. No dilutive funding / placings required.
Absolutely amazing stuff.
Only disappointing thing is the lack of support pharma gets in the UK. They’re having to trial this in the US, which means it’ll be a major US pharma who takes up a licencing deal or buys up the platform and then sells it back to the NHS for billions a year.